Document is current

Any future updates will be listed below

Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRASmetastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study)

Crossref DOI link: https://doi.org/10.1186/1471-2407-14-865

Published Online: 2014-11-22

Published Print: 2014-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark